Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MXI1
REST API REST API
Homo sapiens
MXI1 is differentially expressed in 326 experiments: 104 organism parts: bone marrow, cerebellum, ... (102 more);, 159 disease states: normal, glioblastoma, ... (157 more);, 92 cell types 399 cell lines 39 compound treatments and 69 other conditions.
Synonyms MXI, bHLHc11, MXD2, MAD2
Orthologs MXI1 (Gallus gallus)   Q9NDP3_CIOIN (Ciona intestinalis)   Mxi1 (Mus musculus)   mxi1 (Danio rerio)   Q0VCQ3_BOVIN (Bos taurus)   Mxi1 (Rattus norvegicus)   MXI1_RAT (Rattus norvegicus)   mxi1 (Xenopus laevis)   MXI1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, negative regulation of cell proliferation, transcription corepressor activity, cytoplasmic sequestering of transcription factor, nucleus, negative regulation of transcription from RNA polymerase II promoter
InterPro Term HLH_DNA-bd
UniProt Accession Q96E53, Q5V9L6, P50539, B1ANN6, B1ANN9, B1ANN8
Gene-Disease Assocation PROSTATE CANCER
Search EB-eye ENSG00000119950
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
UACC812
2
E-MTAB-37, E-MTAB-62
BT474
2
E-MTAB-37, E-MTAB-62
MCF-7
2
E-GEOD-20081, E-GEOD-5823
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
393 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (50 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-GEOD-6740, E-AFMX-5
centroblast
2
E-TABM-702, E-GEOD-15271
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
activated natural killer cell (supplemented for IL2 for 24 hours)
1
E-TABM-702
ADC
1
E-GEOD-19188
leydig cell
1
E-MTAB-25
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (54 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-GEOD-4412, E-MEXP-567
prostate carcinoma
3
E-MTAB-62, E-GEOD-96, E-MEXP-2034
AIDS-KS, KSHV-
2
E-MTAB-62, E-MEXP-66
obesity
2
E-MTAB-62, E-GEOD-2508
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-57
153 more value(s).


Compound treatment

studied in E-GEOD-697, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (28 experiments)

Factor Value U/D Experiments
none
5
10
E-MEXP-1601, E-GEOD-20719, E-GEOD-1923, E-GEOD-5824, E-TABM-868, ... (15 experiments)
saline
1
E-GEOD-3026
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
unknown
1
E-GEOD-7307
AMP
1
E-MEXP-2285
U0126
1
E-GEOD-697
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-MEXP-1828, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (9 experiments)

Disease staging
studied in E-GEOD-89, E-TABM-147, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, E-TABM-440, ... (17 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-GEOD-16363, E-GEOD-430, ... (31 experiments)

Infection
studied in E-GEOD-12254, E-GEOD-9723, E-MEXP-561, E-GEOD-980, E-GEOD-17400, ... (8 experiments)

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-19136, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.343 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM